…
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -29.00M | -24.50M | -30.98M | -30.34M | -23.46M |
| Net income | -28.70M | -21.70M | -26.94M | -24.59M | -20.32M |
| Selling general administrative | 30.30M | 40.50M | 43.93M | 41.54M | 27.12M |
| Selling and marketing expenses | - | 15.20M | - | - | - |
| Gross profit | 1.90M | 15.30M | 13.12M | 11.59M | 4.03M |
| Reconciled depreciation | 2.50M | 3.40M | 3.11M | 2.56M | 1.60M |
| Ebit | -28.60M | -24.10M | -30.76M | -29.91M | -23.04M |
| Ebitda | -26.10M | -20.70M | -27.58M | -27.31M | -21.25M |
| Depreciation and amortization | 2.50M | 3.40M | 3.18M | 2.59M | 1.79M |
| Operating income | -28.80M | -24.80M | -30.76M | -29.91M | -23.04M |
| Other operating expenses | 32.80M | 55.60M | 57.92M | 55.07M | 32.47M |
| Interest expense | 0.40M | 0.40M | 0.29M | 0.46M | 0.17M |
| Tax provision | -1.20M | -2.80M | -4.04M | -5.74M | -3.15M |
| Interest income | 0.20M | 0.70M | 0.07M | 0.03M | 0.18M |
| Net interest income | -0.20M | 0.30M | -0.22M | -0.33M | 0.01M |
| Income tax expense | -1.20M | -2.80M | -4.04M | -5.74M | -3.15M |
| Total revenue | 4.00M | 30.80M | 27.17M | 25.16M | 9.43M |
| Total operating expenses | 30.70M | 40.10M | 43.88M | 41.49M | 27.07M |
| Cost of revenue | 2.10M | 15.50M | 14.05M | 13.58M | 5.39M |
| Total other income expense net | -0.20M | 0.50M | -0.22M | -0.43M | -0.42M |
| Net income from continuing ops | -27.80M | -21.70M | -26.94M | -24.59M | -20.32M |
| Net income applicable to common shares | - | - | - | -24.59M | -20.32M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 65.00M | 76.60M | 75.34M | 100.61M | 93.50M |
| Intangible assets | 0.50M | 7.10M | 8.08M | 8.69M | 10.27M |
| Other current assets | 43.70M | 3.40M | - | 9.13M | 8.61M |
| Total liab | 22.60M | 16.80M | 25.93M | 27.29M | 30.70M |
| Total stockholder equity | 42.40M | 59.80M | 49.40M | 73.32M | 62.81M |
| Deferred long term liab | - | - | - | 0.36M | 0.49M |
| Other current liab | 16.90M | 3.60M | 2.87M | 4.22M | 4.07M |
| Common stock | 0.40M | 0.40M | 0.18M | 0.18M | 0.16M |
| Capital stock | 0.40M | 0.40M | 0.18M | 0.18M | 0.16M |
| Retained earnings | -173.10M | -144.40M | -122.70M | -95.76M | -71.16M |
| Other liab | - | - | - | 2.38M | 2.32M |
| Good will | 0.00M | 19.10M | 19.56M | 18.56M | 18.26M |
| Other assets | - | 0.00M | - | 2.21M | 1.08M |
| Cash | 8.70M | 3.00M | 13.10M | 43.53M | 45.09M |
| Total current liabilities | 20.50M | 9.90M | 17.48M | 19.74M | 21.84M |
| Current deferred revenue | - | -0.20M | - | 0.21M | 2.00M |
| Net debt | -4.30M | 5.30M | -1.41M | -32.98M | -32.74M |
| Short term debt | 2.40M | 3.10M | 5.62M | 5.38M | 5.81M |
| Short long term debt | 2.20M | 2.50M | 1.59M | 4.71M | 5.19M |
| Short long term debt total | 4.40M | 8.30M | 11.68M | 10.56M | 12.35M |
| Other stockholder equity | 192.00M | 180.90M | 171.92M | 168.90M | 133.81M |
| Property plant equipment | - | - | - | 8.60M | 3.38M |
| Total current assets | 56.40M | 37.90M | 33.69M | 61.17M | 60.51M |
| Net tangible assets | - | - | - | 46.42M | 34.77M |
| Short term investments | - | 15.50M | - | - | - |
| Net receivables | 1.30M | 7.90M | 6.76M | 8.76M | 8.37M |
| Long term debt | 1.90M | 4.40M | 4.89M | 3.79M | 5.16M |
| Inventory | 2.70M | 8.10M | 9.32M | 8.50M | 6.81M |
| Accounts payable | 0.90M | 2.70M | 9.00M | 9.92M | 9.96M |
| Accumulated other comprehensive income | 23.10M | 22.90M | - | - | - |
| Common stock total equity | - | - | - | - | 0.16M |
| Non currrent assets other | 0.10M | 0.20M | 2.27M | 0.15M | 0.61M |
| Non current assets total | 8.60M | 38.70M | 41.65M | 39.44M | 32.99M |
| Capital lease obligations | 0.30M | 1.40M | 1.73M | 2.06M | 2.01M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 15.30M | -18.30M | -5.96M | -7.84M | -20.97M |
| Change to liabilities | - | - | - | 1.88M | 1.69M |
| Total cashflows from investing activities | 15.30M | -18.30M | - | -7.84M | -20.97M |
| Net borrowings | 5.80M | -1.20M | - | -2.21M | 1.17M |
| Total cash from financing activities | 16.20M | 29.80M | 0.45M | 31.99M | 1.33M |
| Net income | -27.80M | -21.70M | -26.94M | -24.59M | -20.32M |
| Change in cash | 9.30M | -10.10M | -30.44M | -1.56M | -35.96M |
| Begin period cash flow | 3.00M | 13.10M | 43.53M | 45.09M | 81.05M |
| End period cash flow | 12.30M | 3.00M | 13.10M | 43.53M | 45.09M |
| Total cash from operating activities | -22.20M | -21.60M | -24.98M | -26.01M | -16.28M |
| Issuance of capital stock | 11.10M | 31.70M | 0.00M | 34.21M | 0.16M |
| Depreciation | 2.50M | 3.40M | 3.11M | 2.56M | 1.60M |
| Other cashflows from investing activities | 15.60M | -14.70M | - | 0.03M | 0.20M |
| Change to inventory | 0.70M | -0.40M | -0.35M | -2.97M | 0.77M |
| Change to account receivables | -1.00M | -1.40M | - | -3.17M | -0.39M |
| Sale purchase of stock | - | - | - | - | 0.16M |
| Other cashflows from financing activities | -0.70M | -0.70M | 2.02M | -0.37M | 1.66M |
| Change to netincome | - | - | - | 0.28M | 0.38M |
| Capital expenditures | 0.40M | 1.20M | 3.27M | 6.12M | 0.58M |
| Change in working capital | -0.10M | -5.50M | -2.75M | -4.26M | 2.06M |
| Stock based compensation | 1.50M | 1.20M | 1.40M | 2.56M | 0.73M |
| Other non cash items | 1.70M | 1.00M | 0.19M | 0.43M | -0.02M |
| Free cash flow | -22.60M | -22.80M | -28.26M | -32.13M | -16.86M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CREO Creo Medical Group PLC |
- -% |
11.25 | - | - | 199.36 | 0.74 | 6.21 | 8.16 |
| SN Smith & Nephew PLC |
-14.00 1.23% |
1122.50 | 23.24 | 12.47 | 1.70 | 2.59 | 2.67 | 10.76 |
| NIOX NIOX Group PLC |
2.00 2.99% |
69.00 | 28.20 | 18.73 | 4.84 | 3.41 | 4.35 | 13.85 |
| EKF EKF Diagnostics Holdings Plc |
-0.40 1.61% |
24.40 | - | 34.97 | 2.02 | 1.46 | 1.72 | 7.01 |
| AOTI AOTI Inc |
-1.00 0.77% |
129.00 | 18.25 | 8.10 | 0.64 | 2.76 | 0.94 | 8.31 |
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, it provides endotherapy accessories comprising injection needles, haemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, the company offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig Jonathan Gulliford | CEO & Exec. Director | 1971 |
| Prof. Christopher Paul Hancock | Founder, CTO & Exec. Director | 1968 |
| Mr. Richard John Rees ACA | CFO, Company Sec. & Exec. Director | 1977 |
| Mr. David Gerard Woods | Chief Commercial Officer & Exec. Director | 1966 |
| Mr. Phil Hales | Sales & Marketing Director | NA |
| Mr. Craig Jonathan Gulliford | CEO & Executive Director | 1970 |
| Prof. Christopher Paul Hancock | Founder & CTO | 1967 |
| Mr. Richard John Rees ACA | CFO & Executive Director | 1976 |
| Mr. David Gerard Woods | Chief Commercial Officer | 1965 |
| Mr. Richard Gary Craven | Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.